Prevention and post-exposure management of occupational exposure to Ebola virus
Date
2024
Authors
Moso, M.A.
Lim, C.K.
Williams, E.
Marshall, C.
McCarthy, J.
Williamson, D.A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
The Lancet Infectious Diseases, 2024; 24(2):e93-e105
Statement of Responsibility
Michael A Moso, Chuan K Lim, Eloise Williams, Caroline Marshall, James McCarthy, Deborah A Williamson
Conference Name
Abstract
There have been significant advances in the prevention and management of Ebola virus disease (EVD) caused by Zaire Ebola virus (ZEBOV), including the development of two effective vaccines, rVSV-ZEBOV and Ad26.ZEBOV/MVA-BN-Filo. In addition, ZEBOV monoclonal antibodies have become first-line therapy for EVD. However, the 2022–23 outbreak of Sudan Ebola virus (SUDV) in Uganda has highlighted the gap in current therapies and vaccines, whose efficacy is uncertain against non-ZEBOV species. Health-care and laboratory staff working in EVD treatment centres or Ebola virus diagnostic and research laboratories face unique risks relating to potential occupational exposure to Ebola viruses. Given the substantial morbidity and mortality associated with EVD, facilities should have strategies in place to manage occupational exposures, including consideration of post-exposure therapies. In this Review, we discuss currently available evidence for prevention and post-exposure prophylaxis of EVD, including therapies currently under evaluation for SUDV.
School/Discipline
Dissertation Note
Provenance
Description
Published online: September 15, 2023
Access Status
Rights
© 2023 Elsevier Ltd. All rights reserved.